Lisa-jane K. Graham
Chris O'brien Lifehouse, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Journal: EBioMedicine
Published: March 13, 2023
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.
Journal: Translational andrology and urology
Published: May 10, 2021
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Journal: European urology
Published: August 05, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Journal: European urology focus
Published: February 27, 2019
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
Journal: European urology
Published: October 14, 2017
Comparison of 4 commercial kits for the extraction of circulating DNA from plasma.
Journal: Cancer genetics
Published: June 09, 2017
Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Journal: Bioorganic & medicinal chemistry
Published: October 10, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026